Navigation Links
CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Date:9/11/2007

KIRKLAND, Wash., Sept. 11 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) has entered into a collaborative research agreement with physician scientists at the Cleveland Clinic Foundation of Cleveland, Ohio. The goal of the collaboration is to investigate the presence and regulation of heart receptors involved in stem cell trafficking in normal and diseased human hearts, using CellCyte's proprietary compounds.

CellCyte Genetics is developing stem cell enabling therapeutic products designed to allow more efficient delivery and significantly increased retention of adult stem cells to diseased organs, such as the heart. The goal of this therapy is to increase the number of stem cells delivered to a damaged organ, thereby increasing organ healing and functional restoration. The Company's first product in development, CCG-TH30, is designed to send autologous bone-marrow-derived (adult) stem cells to the heart of patients after a heart attack. In preclinical models, CCG-TH30 has been shown to increase the retention of stem cells up to as much as 80% compared to conventional methods, which achieve only up to about 7%. Importantly, CellCyte's product can be delivered intravenously through the patients' circulatory system without an invasive procedure.

The lead investigators of the project at Cleveland Clinic Foundation are Dr. Wilson Tang M.D. and Dr. Sathyamangla Prasad Ph.D., both accomplished and renowned scientists in the field of cardiac biology. Dr. Tang is also a physician and key opinion leader in cardiac medicine.

The Cleveland Clinic Foundation scientists will analyze heart tissue samples of heart failure patients for the presence of surface receptors that are hypothesized to play an important role in the interaction of stem cells with the heart. These studies are expected to provide valuable novel information that will increase the understanding of cardiac regeneration and will thereby sup
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , 21 de mayo de 2013 La ... compañías filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y ... para su junta. Guy Mayer, un ejecutivo ortopédico experimentado, ... David Johnson , un experto refutado ... Antes de unirse a OSI como presidente ...
(Date:5/21/2013)... PHILADELPHIA , May 21, 2013 ... and impressive new product developments at the Special Libraries Association ... years of unerring focus on product literature databases and workflow ... mark the occasion," said founding director Nigel Johnson ... developments of benefit to our clients and what better forum ...
(Date:5/21/2013)... 21, 2013  Decision Resources, one of ... for pharmaceutical and healthcare issues, finds that ... key efficacy endpoints, including overall survival and ... influence over surveyed U.S. and European oncologists, ... HER2-negative breast cancer. The two novel emerging ...
Breaking Medicine Technology:Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
...  - Agreement allows development for potential ... SHP, NASDAQ: SHPGY ), the global specialty ... rights to develop and market Resolor ® (prucalopride) ... Janssen Pharmaceutica N.V.  Terms of the agreement have not ...
... 2012  Transvaginal mesh will undergo new safety studies, as ... Elk & Elk are currently investigating transvaginal mesh claims. ... more than 30 transvaginal surgical mesh manufacturers, including Johnson ... to perform post-market safety studies after a fivefold increase ...
Cached Medicine Technology:Shire Acquires US Rights to Resolor(R) (prucalopride) 2Shire Acquires US Rights to Resolor(R) (prucalopride) 3Shire Acquires US Rights to Resolor(R) (prucalopride) 4Ohio Injury Lawyers Support FDA's Decision for Further Testing of Transvaginal Mesh 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 Artisan ... EB-5 Investment Summit: Dealmakers Conference in Long Beach, ... will focus on exploring alternative finance through EB-5 ... latest market, legal and economic information, and updates ... legal professionals within the EB-5 industry. , ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... MedMar Healing Center announces their ... Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, ... drive. The goal is to raise food to help area ... their families in recent years. , “We like being ... in need,” explains Douglas Chloupek of MedMar Healing Center. “Taking ...
(Date:5/21/2013)... CINCINNATIUsing the Department of Defense Serum Repository (DoDSR), University ... biomarkers for inflammatory bowel disease (IBD), which could help ... not yet shown symptoms. , This finding, the first ... MD, is being presented via podium presentation by staff ... Disease Week 2013, being held May 18-21 in Orlando, ...
(Date:5/21/2013)... May 21, 2013 Today, Zane Benefits, ... and FSA accounts. Zane Benefits, which provides comprehensive ... is the leader in defined contribution and ... . , According to Zane Benefits’ website, the Affordable ... signed into law in 2010 and impacts many areas ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3
... that sensible drinking, which can be likened to about two ... two drinks for women, may actually be a way to ... the risk of death, Italian researchers have said. ... their consumption, but people who already regularly consume low to ...
... sharp reductions in human immunodeficiency virus (HIV) levels, and ... with HIV infection. ,If the good results ... be a welcome addition to the existing treatment options ... study, led by Dr Martin Markowitz of The Rockefeller ...
... A multicenter study on treating common ear infections in ... of evidence that favors antibiotic ear drops over antibiotics ... a UT Southwestern Medical Center researcher reports. ... ear drops performed better and faster in treating middle ...
... explosion some 19 years ago had double hand transplant done on ... Spain, and worldwide first on a woman. ,A surgery ... ,The leading surgeon Pedro Cavadas said the patient was ... should get back full use of her hands within five to ...
... has always been regarded as one of the toughest and ... and also adds that the workload// and strain makes them ... and January 2006 on nearly 19,000 nurses, which included registered ... ,The overall observation was that nurses face a variety of ...
... his family spent a week of mental trauma after a private ... cleared of the disease after tests at a government hospital. ... positive for HIV by doctors at a private nursing home on ... sorrow with the fear of death hanging over him. ...
Cached Medicine News:Health News:New Drug Offers Promise as Single Treatment for HIV 2Health News:Antibiotic Ear Drops Favored Over Oral Antibiotics for Ear Infections 2Health News:Panic Gripped Young Man After Wrong Diagnosis With HIV 2
The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...
... is specially designed for ... in standard 500ml bags, ... AS3864 1997. Quiet hermetic ... CFC Free refrigerant with ...
... a direct competitive EIA for the ... serum or plasma. A specific agent ... it available for antibody binding. Testosterone ... linked to fluorescein isothiocyanate (FITC) and ...
... Vitamin B6 makes it possible to determine ... precise method. The kits includes all reagents ... separation of the samples with,exception of the ... the simultaneous handling of many analytes in ...
Medicine Products: